首页> 外文期刊>Journal of hypertension >Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses
【24h】

Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses

机译:降低血压对高血压预后的影响:5.各种抗高血压药物的头对头比较-概述和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background and objectives:We have recently published an overview and meta-analysis of the effects of the five major classes of blood pressure-lowering drugs on cardiovascular outcomes when compared with placebo. However, possible differences in effectiveness of the various classes can correctly be estimated only by head-to-head comparisons of different classes of agents. This has been the objective of a new survey and meta-analysis.Methods:A database search between 1966 and August 2014 identified 50 eligible randomized controlled trials for 58 two-drug comparisons (247006 patients for 1029768 patient-years). Risk ratios and their 95% confidence intervals of seven outcomes were estimated by a random-effects model.Results:The effects of all drug classes are not significantly different on most outcomes when their blood pressure effect is equivalent. However, there are also significant differences involving almost all classes of drugs. When compared to all other classes together, diuretics are superior in preventing heart failure; beta-blockers less effective in preventing stroke; calcium antagonists superior in preventing stroke and all-cause death, but inferior in preventing heart failure; angiotensin-converting enzyme inhibitors more effective in preventing coronary heart disease and less in preventing stroke; angiotensin receptor blockers inferior in preventing coronary heart disease; and renin-angiotensin system blockers more effective in preventing heart failure. When stratifying randomized controlled trials according to total cardiovascular risk, no drug class was found to change in effectiveness with the level of risk.Conclusions:The results of all available evidence from head-to-head drug class comparisons do not allow the formulation of a fixed paradigm of drug choice valuable for all hypertensive patients, but the differences found may suggest specific choices in specific conditions, or preferable combinations of drugs.
机译:背景与目的:我们最近发表了与安慰剂相比对五种主要降压药物对心血管结局的影响的概述和荟萃分析。但是,只有通过不同类别代理的面对面比较,才能正确估计各种类别有效性的可能差异。方法:1966年至2014年8月之间的数据库搜索确定了50项符合条件的随机对照试验,进行了58种双药比较(247006例患者,共1029768例患者-年)。通过随机效应模型评估了七个结果的风险比及其95%置信区间。结果:当血压效果相同时,所有药物类别对大多数结果的影响均无显着差异。但是,几乎所有类别的药物也存在显着差异。与其他所有类别一起使用时,利尿剂在预防心力衰竭方面具有优势。 β受体阻滞剂在预防中风方面不太有效;钙拮抗剂在预防中风和全因死亡方面表现优异,但在预防心力衰竭方面表现不佳;血管紧张素转换酶抑制剂在预防冠心病方面更有效,而在预防中风方面则较少;血管紧张素受体阻滞剂在预防冠心病方面较差;肾素-血管紧张素系统阻滞剂可更有效地预防心力衰竭。当根据总心血管风险对随机对照试验进行分层时,未发现任何药物类别会随风险水平而改变有效性。结论:头对头药物类别比较的所有可用证据的结果均不允许制定固定的药物选择范式对所有高血压患者都很有价值,但发现的差异可能表明在特定条件下进行特定选择,或优选药物组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号